VolitionRX Limited (VNRX) CEO Cameron Reynolds on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha]
VolitionRX Limited (VNRX)
NASDAQ:AMEX Investor Relations:
ir.volitionrx.com
Company Research
Source: Seeking Alpha
VolitionRX Limited (VNRX) CEO Cameron Reynolds on Q1 2019 Results - Earnings Call Transcript VolitionRX Limited (NYSEMKT: VNRX Company Participants Scott Powell - Executive Vice President, Investor Relations Cameron Reynolds - Founder, Chief Executive Officer, President and Director Conference Call Participants Jason McCarthy - Maxim Group Jonas Peciulis - Edison Investment Research Bruce Jackson - The Benchmark Company Brian Marckx - Zacks Investment Research Operator Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRX Limited First Quarter 2019 Earnings Conference Call. [Operator Instructions] This conference is recorded today, May 9, 2019 I would now like to turn the conference over to Scott Powell, Executive Vice President of Investor Relations. Please go ahead. Thank you, and welcome everyone to today's earnings conference call for VolitionRX Limited. This call will cover VolitionRX's financial and operating results for the first quarter ended Mar
Show less
Read more
Impact Snapshot
Event Time:
VNRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNRX alerts
High impacting VolitionRX Limited news events
Weekly update
A roundup of the hottest topics
VNRX
News
- VolitionRx Limited (NYSE: VNRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Antech's Breakthrough AI-powered Radiology and Targeted Cancer Screening Tools Now Available, Unleashing New Chapter for Veterinary Diagnostics [Yahoo! Finance]Yahoo! Finance
- VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture -PCR) 2) Nu.Q NET for Sepsis [Yahoo! Finance]Yahoo! Finance
- VolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- VolitionRx Limited (NYSE: VNRX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $2.50 price target on the stock.MarketBeat
VNRX
Earnings
- 11/14/23 - Beat
VNRX
Sec Filings
- 3/26/24 - Form D
- 3/25/24 - Form 10-K
- 3/25/24 - Form 8-K
- VNRX's page on the SEC website